MetLife Investment Management
CATX icon

MetLife Investment Management’s Perspective Therapeutics CATX Stock Holding History

MetLife Investment Management’s Portfolio CATX Stock Details CATX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$209K Buy
61,355
+28,276
+85% +$107K ﹤0.01% 2395
2026
Q1 		$138K Buy
33,079
+16,362
+98% +$69.1K ﹤0.01% 2395
2025
Q4 		$46K Sell
16,717
-12,842
-43% -$36.6K ﹤0.01% 2733
2025
Q3 		$101K Sell
29,559
-1,994
-6% -$7.27K ﹤0.01% 2644
2025
Q2 		$109K Buy
31,553
+243
+0.8% +$642 ﹤0.01% 2503
2025
Q1 		$66.7K Buy
31,310
+9,082
+41% +$27.3K ﹤0.01% 2658
2024
Q4 		$70.9K Sell
22,228
-8,937
-29% -$73K ﹤0.01% 2708
2024
Q3 		$416K Buy
31,165
+19,137
+159% +$255K ﹤0.01% 1880
2024
Q2 		$120K Buy
+12,028
New +$174K ﹤0.01% 2513

Other funds holding CATX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

MetLife Investment Management's CATX Position: Q2 2026 in Review

MetLife Investment Management increased its Perspective Therapeutics (CATX) stake by 85% in Q2 2026, buying an estimated $107K and bringing the position to 61,355 shares worth $209K. The position accounts for ﹤0.01% of the portfolio, ranked #2395.

MetLife Investment Management first reported a position in CATX in Q2 2024 and has held it in 9 quarters since. The position peaked at $416K in Q3 2024. 131 funds tracked by Wall St. Rank hold CATX as of Q2 2026.

  • MetLife Investment Management held 61,355 shares of Perspective Therapeutics worth $209K as of Q2 2026.
  • MetLife Investment Management bought 28,276 Perspective Therapeutics shares in Q2 2026, an estimated $107K.
  • Perspective Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2395 holding.
  • MetLife Investment Management first reported a position in Perspective Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • MetLife Investment Management's Perspective Therapeutics position peaked at $416K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Perspective Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.